Literature DB >> 14654667

Future role of large neutral amino acids in transport of phenylalanine into the brain.

Reuben Matalon1, Sankar Surendran, Kimberlee Michals Matalon, Stephen Tyring, Michael Quast, Wei Jinga, Edward Ezell, Sylvia Szucs.   

Abstract

OBJECTIVE: The treatment of phenylketonuria (PKU) in children and adults has been difficult because of erosion of dietary adherence, leading to poor school performance, impairment of executive functioning, loss of IQ, and deterioration of white matter in the brain. Mutant PKU mice produced by exposure to N-ethyl-N'-nitrosourea (ENU) were used to examine the effect of large neutral amino acid (LNAA) supplementation on brain and blood phenylalanine (Phe).
METHODS: Mice with PKU, genotype ENU 2/2 with features of classical PKU, were supplemented with LNAA while on a normal diet. Two dosages of LNAA were given 0.5 g/kg and 1.0 g/kg by gavage. Blood Phe was determined in the experimental, control, and sham-treated mice. Brain Phe was determined by magnetic resonance spectroscopy after perchloric acid extraction. Branched-chain amino acid transferase (BCAT) was determined in brain as a marker for energy metabolism.
RESULTS: Blood Phe was reduced in the LNAA-treated mice by an average of 15% (0.5 g/kg) and 50% (1.0 g/kg) in 48 hours. There was a sustained decrease in the blood Phe levels over a 6-week trial. The untreated mice and sham-treated mice maintained high blood Phe throughout the experiments. Brain Phe level determined by magnetic resonance spectroscopy showed a decline of 46% after the LNAA treatment. BCAT levels were lower (33%) in the ENU 2/2 mice compared with wild-type. The BCAT normalized in mice with PKU that were treated with LNAA.
CONCLUSION: The results suggest that giving LNAA lowered brain and blood Phe levels in mice with PKU. Energy metabolism generated from BCAT also improved in mice with PKU after treatment with LNAA. Data from the mice suggest that LNAA should be considered among the strategies to treat PKU in humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14654667

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  18 in total

1.  Clinical therapeutics for phenylketonuria.

Authors:  Jaspreet Singh Kochhar; Sui Yung Chan; Pei Shi Ong; Lifeng Kang
Journal:  Drug Deliv Transl Res       Date:  2012-08       Impact factor: 4.617

2.  Large neutral amino acids in the treatment of phenylketonuria (PKU).

Authors:  R Matalon; K Michals-Matalon; G Bhatia; E Grechanina; P Novikov; J D McDonald; J Grady; S K Tyring; F Guttler
Journal:  J Inherit Metab Dis       Date:  2006-09-21       Impact factor: 4.982

3.  Hyperphenylalaninemia Correlated with Global Decrease of Antioxidant Genes Expression in White Blood Cells of Adult Patients with Phenylketonuria.

Authors:  Charlotte Veyrat-Durebex; Christelle Debeissat; Hélène Blasco; Franck Patin; Hélène Henique; Patrick Emond; Catherine Antar; Valérie Gissot; Olivier Herault; François Maillot
Journal:  JIMD Rep       Date:  2017-03-15

Review 4.  Nutritional management of PKU with glycomacropeptide from cheese whey.

Authors:  D M Ney; S T Gleason; S C van Calcar; E L MacLeod; K L Nelson; M R Etzel; G M Rice; J A Wolff
Journal:  J Inherit Metab Dis       Date:  2008-10-29       Impact factor: 4.982

Review 5.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

Review 6.  Large neutral amino acids in the treatment of PKU: from theory to practice.

Authors:  Francjan J van Spronsen; Martijn J de Groot; Marieke Hoeksma; Dirk-Jan Reijngoud; Margreet van Rijn
Journal:  J Inherit Metab Dis       Date:  2010-10-26       Impact factor: 4.982

7.  Interpretation of plasma amino acids in the follow-up of patients: the impact of compartmentation.

Authors:  Claude Bachmann
Journal:  J Inherit Metab Dis       Date:  2008-01-31       Impact factor: 4.982

8.  Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria.

Authors:  Angel L Pey; Ming Ying; Nunilo Cremades; Adrian Velazquez-Campoy; Tanja Scherer; Beat Thöny; Javier Sancho; Aurora Martinez
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

9.  Classical maple syrup urine disease and brain development: principles of management and formula design.

Authors:  Kevin A Strauss; Bridget Wardley; Donna Robinson; Christine Hendrickson; Nicholas L Rider; Erik G Puffenberger; Diana Shellmer; Diana Shelmer; Ann B Moser; D Holmes Morton
Journal:  Mol Genet Metab       Date:  2010-01-12       Impact factor: 4.797

Review 10.  Pathogenesis of CNS involvement in disorders of amino and organic acid metabolism.

Authors:  S Kölker; S W Sauer; G F Hoffmann; I Müller; M A Morath; J G Okun
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.